Hepcidin as a therapeutic target in iron overload

Area of Science:

• * Hematology
• * Molecular Medicine
• * Therapeutics

Background:

• * The hepcidin-ferroportin axis is critical in iron metabolism; its dysregulation drives iron overload pathogenesis.
• * Hereditary hemochromatosis and iron-loading anemias involve hepcidin deficiency, highlighting hepcidin as a therapeutic target.
• * Current iron overload treatments do not address hepcidin deficiency and may worsen it.

Purpose of the Study:

• * To summarize preclinical and clinical trial results of hepcidin-targeting therapies for iron overload.
• * To evaluate the therapeutic potential of modulators of hepcidin expression and hepcidin mimetics.
• * To discuss challenges and future directions for hepcidin-based iron overload treatments.

Main Methods:

• * Review of preclinical studies in iron overload models.
• * Analysis of clinical trial data for hepcidin-targeting therapies.
• * Evaluation of therapeutic strategies involving hepcidin modulation or mimicry.

Main Results:

• * Emerging therapies modulating hepcidin expression or mimicking hepcidin demonstrate significant therapeutic promise.
• * These novel strategies offer a potential solution for conditions characterized by hepcidin deficiency.
• * Further research is needed to optimize dosing and specificity for iron metabolism pathways.

Conclusions:

• * Hepcidin-targeting therapies represent a novel and promising approach to managing iron overload disorders.
• * Challenges include optimizing treatment windows, ensuring pathway specificity, and conducting long-term safety/efficacy studies.
• * These therapies may also benefit other iron dysregulation conditions, such as anemia of chronic disease.